Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.59), $0.27 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $9.39 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.